Mechanisms Underlying the Comorbidity of Schizophrenia and Type 2 Diabetes Mellitus

Yutaka Mizuki, Shinji Sakamoto, Yuko Okahisa, Yuji Yada, Nozomu Hashimoto, Manabu Takaki, Norihito Yamada

Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences (Drs Mizuki, Sakamoto, Okahisa, Yada, Hashimoto, Takaki, and Yamada); Shimonoseki Hospital (Dr Mizuki); Okayama Psychiatric Medical Center (Drs Yada and Hashimoto).

Correspondence: Manabu Takaki, MD, PhD, Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan (manabuta@cc.okayama-u.ac.jp).

Abstract

The mortality rate of patients with schizophrenia is high, and life expectancy is shorter by 10 to 20 years. Metabolic abnormalities including type 2 diabetes mellitus (T2DM) are among the main reasons. The prevalence of T2DM in patients with schizophrenia may be epidemiologically frequent because antipsychotics induce weight gain as a side effect and the cognitive dysfunction of patients with schizophrenia relates to a disordered lifestyle, poor diet, and low socioeconomic status. Apart from these common risk factors and risk factors unique to schizophrenia, accumulating evidence suggests the existence of common susceptibility genes between schizophrenia and T2DM. Functional proteins translated from common genetic susceptibility genes are known to regulate neuronal development in the brain and insulin in the pancreas through several common cascades. In this review, we discuss common susceptibility genes, functional cascades, and the relationship between schizophrenia and T2DM. Many genetic and epidemiological studies have reliably associated the comorbidity of schizophrenia and T2DM, and it is probably safe to think that common cascades and mechanisms suspected from common genes’ functions are related to the onset of both schizophrenia and T2DM. On the other hand, even when genetic analyses are performed on a relatively large number of comorbid patients, the results are sometimes inconsistent, and susceptibility genes may carry only a low or moderate risk. We anticipate future directions in this field.

Key Words: DISC1, kalirin, ARHGEF11, Akt/GSK3β, Wnt/β-catenin

Introduction

Schizophrenia is found in all cultures and appears to affect 0.5% to 1.5% of people during their lifetime (Pedersen et al., 2014). Due to its early age of onset and subsequent tendency to persist chronically, it produces great suffering for patients and their family members (Weinberger and Harrison, 2011). The mortality rate of patients with schizophrenia is twice as high as that of the general population, and their life expectancy is 10–20 years shorter (Crump et al., 2013; Lawrence et al., 2013). Although suicide and other unnatural causes account for more than 10% of the excess mortality, a substantial proportion of this excess mortality is due to the increased comorbidity of various medical illnesses in patients with schizophrenia (Crump et al., 2013; Lawrence et al., 2013; Olfson et al., 2015). Patients with schizophrenia have an increased risk for development of type 2 diabetes mellitus (T2DM). The prevalence of T2DM in patients with schizophrenia is approximately 6% to 21%, 2 to 3 times higher than in the general population (Mitchell et al., 2013; Stubbs et al., 2015). T2DM manifests as persistent hyperglycemia due
to pancreatic beta-cell dysfunction, which leads to long-term complications. T2DM is a major risk factor for cardiovascular disease, and cardiovascular disease is the main cause of a substantial proportion of excess deaths of patients with schizophrenia (Murray et al., 2012; Lawrence et al., 2013; Olsson et al., 2015).

The mechanisms of the increasing prevalence of T2DM in patients with schizophrenia are multifactorial. T2DM and schizophrenia are caused by shared etiological factors (Ward and Druss, 2015). Traditional risk factors include a sedentary lifestyle and poor diet (Ward and Druss, 2015). Risk factors unique to schizophrenia include low socioeconomic status, cognitive dysfunction, and iatrogenic risk during treatment with antipsychotics (Ward and Druss, 2015). Some evidence suggests that a longer duration of schizophrenia increases the risk for diabetes (Philippe et al., 2005; Nuevo et al., 2011). Patients who have had schizophrenia for more than 25 years have nearly twice the risk for diabetes as those with less than 25 years since the first admission to hospital (Philippe et al., 2005). It has been found that impaired hormonal regulation of appetite, in terms of low leptin and high insulin levels, often occurs in early psychosis before antipsychotic treatment (Misiak et al., 2019; Lis et al., 2020a, 2020b). Hence, schizophrenia itself is a risk for increased onset of diabetes. Apart from these traditional risk factors and risk factors unique to schizophrenia, recent studies show an elevated risk of T2DM among drug-naïve or first-episode patients with schizophrenia and their relatives (Perry et al., 2016; Pillinger et al., 2017; Rajkumar et al., 2017). A recent systematic review and meta-analysis of glucose homeostasis in unaffected first-degree relatives of schizophrenia patients suggested impaired glucose tolerance in this population as well (Misiak et al., 2020). Thus, previous evidence has strongly suggested that schizophrenia and T2DM are caused by multiple genetic variants (Gough and O’Donovan, 2005). Multiple twin and family studies and heritability of intermediate phenotypes provide convincing evidence for an important role of the genetic etiologies, respectively (Das and Elbein, 2006; Demjaha et al., 2012). The risk of T2DM in patients with psychoses such as schizophrenia is elevated two- to fourfold in association with a positive family history of diabetes (Foley et al., 2014; Chung and Miller, 2020). Further, one-half of patients with schizophrenia have been reported to have a family history of T2DM compared with 4.6% of healthy adult controls (Bushe and Holt, 2004). Interestingly, the polygenic risk score related to the onset of schizophrenia is also associated with insulin resistance in first-episode and antipsychotic-naïve patients with schizophrenia (Tomasik et al., 2019). Thus, schizophrenia and T2DM may influence each other and share susceptibility gene variants.

Accumulating evidence indicates that potential environmental risk factors affecting both the premorbid phase and after the onset of schizophrenia include exposure to stress in early life, poor dietary habits, and a sedentary life style, as noted above. Stress leads to the alteration of several biological mechanisms that has been termed “allostasis” (Misiak et al., 2014). These processes enable adaptation to novel situations. However, their prolonged and cumulative activation exerts systemic and detrimental effects called the allostatic load (AL) (Juster et al., 2016; Misiak, 2019). The AL concept can be a useful framework for apprehending biological dysregulations related to chronic stress. Biological alterations associated with AL (AL mediators) in schizophrenia include a subclinical inflammatory state, enhanced oxidative stress levels, decreased level of neurotrophins, and impaired hypothalamic-pituitary-adrenal (HPA) axis response (Misiak et al., 2014). There are also markers that enable the measurement of AL (AL index). A higher AL index has been associated with a higher severity of positive and depressive symptoms, working memory impairments, lower general functioning, and health outcomes, including all-cause mortality (Misiak, 2019; Piotrowski et al., 2019).

In this review, we describe the comorbidity of schizophrenia and T2DM in genetic and functional pathways. First, we describe susceptibility genes common to schizophrenia and T2DM (Table 1). Second, we discuss molecular mechanisms that might explain a common functional cascade in schizophrenia and T2DM. Third, we describe common mechanisms in schizophrenia and T2DM, such as inflammation, oxidative stress, and HPA axis dysfunction.

Common Susceptibility Genes in Schizophrenia and T2DM

Previous family-based genome-wide linkage studies show that schizophrenia and T2DM have a number of overlapping risk loci, including chromosomes 1p13, 1p36, 1q21–24, 1q25, 2q14, 2q33, 2q36, 3p22, 3q29, 4q25, 5q13, 6p21, 6q25, 7p15, 7p21, 7q21, 7q31, and 9p24 (Lin and Shuldiner, 2010). These loci include gene-rich regions that will harbor multiple common candidate genes for susceptibility to schizophrenia and T2DM. Although many of these loci cover large distances in genomic DNA, chromosome 1q was reported to have a linkage to T2DM by several previous studies (Das and Elbein, 2007; Tziastoudi et al., 2019). This location has also been implicated as a schizophrenia susceptibility locus (Bruzowitz et al., 2000). Therefore, these findings have suggested that chromosome 1q may be remarkably rich in linkage findings for co-occurrence of schizophrenia and T2DM. Within this region of linkage, susceptibility genes for T2DM such as endogenous retrovirus group K member 18 (Herv K-18) and Rho guanine-nucleotide exchange factor 11 (ARHGEF11) (Böttcher et al., 2008) have been found to be associated with schizophrenia among sampled populations (Dickerson et al., 2008; Mizuki et al., 2014).

The most straightforward method to identify the genetic risk for comorbidity of schizophrenia and T2DM is searching for overlapped candidate genes or regions of these 2 individual diseases (Lin and Shuldiner, 2010). Common candidate genes shared by association studies focused on each individual disease are glutathione S-transferase mu 1 (GSTM1), glutathione S-transferase theta 1 (GSTT1), neuropeptide Y (NPY), and proteasome 26S subunit, non-ATPase 9 (PSMD9) (Itokawa et al., 2008; Mizuki et al., 2014). According to data from the Genetic Association Database (http://geneticassociationdb.nih.gov/) (Becker et al., 2004), Catalog of Published Genome-Wide Association Studies (GWAS) (http://www.genome.gov/gwastudies/) (Hindorff et al., 2009), and Type 2 Diabetes Genetic Association Database (http://t2db.khu.ac.kr:8080/) (Lim et al., 2010), there are 196 schizophrenia susceptibility genes and 200 T2DM susceptibility genes. Among them, 14 genes (annexin A1 [ANXA1], apolipoprotein E [APOE], angiotsin 1 converting enzyme [ACE], GSTM1, interleukin 10 [IL10], mithenyltetrahydrofolate reductase [MTHFR], NPY, paraxonase 1 [PON1], superoxide dismutase 2 [SOD2], synapsis II [SYN2], tumor necrosis factor [TNF], uncoupling protein 2 [UCP2], serine racemase [SRR], and tetraspanin 18 [TSPAN18]) are common to both diseases (Liu et al., 2013). These genes could be divided into 2 functional categories. One category is inflammation-associated genes (APOE, IL10, TNF), and the other is genes that are involved in...
| Candidate genes | Location | Official full name | Functions | Method | Samples | References |
|-----------------|----------|-------------------|-----------|--------|---------|------------|
| **Common cascade** |          |                   |           |        |         |            |
| ACE (Upstream of Akt/GSK3) | 17q23.3 | angiotensin I converting enzyme | Hydrolyze angiotensin I into angiotensin 2 | GWAS | SCZ and T2DM database | Liu et al. (2013) |
| ARHGEF11 (Rho GTPase) | 1q23.1 | Rho guanine nucleotide exchange factor 11 | Numerous cellular process, synaptic plasticity | Association study | T2DM (n = 685) vs. Con (n = 461) | Böttcher et al. (2008) |
| BCL9 (Wnt/β-catenin) | 1q21.1 | B-cell CLL/lymphoma 9 | Wnt signaling pathway | Association study | SCZ (n = 5,772) vs. Con (n = 4187) | Li et al. (2011) |
| COMT (Upstream of Akt/GSK3) | 22q11.21 | catechol-O-methyltransferase | Degradation of catecholamines | GWAS or CNV analysis | T2DM (n = 402) vs. Con (n = 1,092) | Luo et al. (2014) |
| **Inflammation** |          |                   |           |        |         |            |
| ANXA1 | 9q21.13 | annexin A1 | Anti-inflammatory activity, endogenous regulator of RhoA | GWAS | SCZ and T2DM database | Liu et al. (2013) |
| APOE | 19q13.32 | apolipoprotein E | Lipid homeostasis and inflammation | GWAS | SCZ and T2DM database | Liu et al. (2013) |
| C4 | 6p21.33 | complement C4 | Encodes complement factor 4, classical activation pathway | Association study | SCZ (n = 28,799) vs. Con (n = 35,986) | Sekar et al. (2016) |
| IL10 | 1q32.1 | interleukin 10 | Cytokine produced by monocytes and lymphocytes | GWAS | SCZ and T2DM database | Liu et al. (2013) |
| **Inflammation & HPA axis** |          |                   |           |        |         |            |
| IL1B | 2q14.1 | interleukin 1 beta | Potent proinflammatory cytokine | Association study | T2DM (n = 200) vs. Con (n = 223) | Achyut et al. (2007) |
| IL6 | 7p15.3 | interleukin 6 | Inflammation and the maturation of B cells | Association study | T2DM Twins (n = 6,720) | Arora et al. (2011) |
|      |        |                   |           |        |         |            | SCZ (n = 621) vs. Con (n = 531) | Kapelski et al. (2015) |
|      |        |                   |           |        |         |            | SCZ (n = 19,022) vs. Con (n = 19,378) | Hudson and Miller (2018) |
| Candidate genes | Location | Official full name | Functions | Method | Samples | References |
|-----------------|----------|-------------------|-----------|--------|---------|------------|
| TNF | 6p21.33 | tumor necrosis factor | Encodes a multifunctional proinflammatory cytokine | GWAS | SCZ and T2DM database | Liu et al. (2013) |
| Oxidative stress | GSTM1 | 1p13.3 | glutathione S-transferase mu 1 | Conjugates reduced glutathione to hydrophobic electrophiles, Detoxification of electrophilic compounds | Association study | SCZ (n = 111) vs. Con (n = 130) | Pae et al. (2004) |
| | | | | | | SCZ (n = 138) vs. Con (n = 133) | Gravina et al. (2011) |
| | | | | | Gamma-glutamyltranspeptidase (ggT) | GWAS | SCZ and T2DM database (T2DM = 1,354) vs. Con (n = 1,666) | Liu et al. (2013) |
| | | | | | | Meta-analysis | T2DM (n = 2,577) vs. Con (n = 4,572) | Zhang et al. (2013) |
| | GSTT1 | 22q11.23 | glutathione S-transferase theta 1 | Conjugates reduced glutathione to hydrophobic electrophiles, Detoxification of electrophilic compounds | Association study | SCZ (n = 118) vs. Con (n = 133) | Gravina et al. (2011) |
| | | | | | | T2DM (n = 1,271) vs. Con (n = 1,470) | Tang et al. (2013) |
| | | | | | | Meta-analysis | T2DM (n = 2,577) vs. Con (n = 4,572) | Zhang et al. (2013) |
| | MTHFR | 1p36.22 | methylenetetrahydrofolate reductase | Catalyzes conversion of methylenetetrahydrofolate to tetrahydrofolate | GWAS | SCZ and T2DM database | Liu et al. (2013) |
| | PON1 | 7q21.3 | paraoxonase 1 | Hydrolyzes toxic metabolites | GWAS | SCZ and T2DM database | Liu et al. (2013) |
| | SOD2 | 6q25.3 | superoxide dismutase 2 | Destroys superoxide anion radicals | GWAS | SCZ and T2DM database | Liu et al. (2013) |
| | TXNRD2 | 22q11.21 | thioredoxin reductase 2 | Regulation of mitochondrial redox homeostasis | CNV analysis | Cumulative scoring evidence based on 32 CNV studies in SCZ | Luo et al. (2014) |
| | | | | | | Association study | T2DM patients with myocardial infarction (n = 166) vs. Con (n = 811) | Kariž et al. (2015) |
| | UCP2 | 11q13.4 | uncoupling protein 2 | Mitochondrial transporter protein | GWAS | SCZ and T2DM database | Liu et al. (2013) |
| | Prolactin pathway | NPY | 7p15.3 | neuropeptide Y | Control of feeding, secretion of gonadotropin-release hormone | Association study | SCZ (n = 212) vs. Con (n = 199) | Itokawa et al. (2003) |
| | | | | | | T2DM (n = 263) vs. Con (n = 469) | Nordman et al. (2005) |
| | | PRL | 6p22.3 | prolactin | Encodes anterior pituitary hormone prolactin | GWAS | SCZ and T2DM database (T2DM = 403) vs. Con (n = 653) | Liu et al. (2013) |
| | DLGAP1 | 18p11.31 | DLG associated protein 1 | Scaffold protein in postsynaptic density, glutamate neurotransmission | CNV analysis | SCZ (n = 662) vs. Con (n = 2,623) | Kirov et al. (2012) |
| | | | | | | T2DM (n = 1,715) | Prabhjan et al. (2016) |
| | Herv K-18 | 1q23.3 | endogenous retrovirus groupCD48 signaling lymphocyte activating (SLAM) gene | Association study | SCZ with T2DM (n = 29) vs. SCZ (n = 200) | Dickerson et al. (2018) |
Table 1.

| Candidate gene | Location | Official full name | Functions | Method | Samples | References |
|----------------|----------|--------------------|-----------|--------|---------|------------|
| IGF2BP2        | 3q27.2   | mRNA binding protein 2 | Embryonic growth and decrease insulin secretion | Association study, GWAS | T2DM (n = 2,201) vs. Con (n = 1,983) | Lyssenko et al. (2008) |
| PACRG          | 6q26     | Molecular chaperone | Chaperone of 26S proteasome | Association study, GWAS | SCZ (n = 554), T2D (n = 822), comorbid (n = 509); controls (n = 1,125) | Hackinger et al. (2018) |
| PSMD9          | 1q24.21  | Chaperone of 26S proteasome complex | Chaperone of 26S proteasome complex | Association study, GWAS | SCZ (n = 1,378) vs. Con (n = 1,351) | Lee et al. (2013) |
| SRR            | 17p13.3  | Catalyzes synthesis of D-amino acid | Synaptogenesis and modulation of neurotransmitter release | GWAS, GWAS and T2DM database | SCZ and T2DM database | Liu et al. (2013) |
| SY2            | 3p21.2   | Synaptogenesis | Tetraspanin families which regulate cell development | GWAS, GWAS and T2DM database | SCZ and T2DM database | Liu et al. (2013) |
| TSPO18         | 1p11.2   | Tetraspanin 18 | | | | |

Other candidate genes, such as insulin-like growth factor 2 mRNA binding protein 2 (IGF2BP2) or transcription factor 7 like 2 (TCF7L2), may also contribute to the genetic basis of the co-occurrence of schizophrenia and T2DM. The IGF2BP2 polymorphisms are associated with vulnerability to schizophrenia in a Han Chinese population (Zhang et al., 2013b) and with impaired pancreatic β-cell function, including lower fasting insulin levels, which reduced glucose-stimulated insulin secretion (Lyssenko et al., 2008). The TCF7L2 polymorphisms have been detected in consistent association with T2DM in multiple ethnic populations, including Japanese, Chinese, Americans, and Asian Indians (Wang et al., 2013). A GWAS in a Greek population identified genomic regions with evidence of colocalizing schizophrenia and T2DM. In this study, the most strongly associated variant resides within an intron of the Parkin coregulated (PACRG) gene in schizophrenia patients with T2DM vs controls, and another variant that reached genome-wide significance resides within the intron of the TCF7L2 gene (Hackinger et al., 2018). However, the findings were negative in a GWAS performed in a Japanese population (Kajjo et al., 2014).

Though common variants of SNP polymorphisms have only small effects, large, rare chromosomal copy number variants (CNVs) identified by comparative genomic analyses are known to increase the risk for schizophrenia and have relatively larger effects (Chen et al., 2015; Bray and O’Donovan, 2018). Of more than 20,000 schizophrenia patients and controls, 8 CNVs (on chromosomes 1q21.1, 2p16.3, 3q29, 7q11.2, 15q13.3, distal 16p11.2, proximal 16p11.2, and the velocardiofacial syndrome region on chromosome 22q11.2) are associated with schizophrenia at a significant genome-wide threshold (CNV and Schizophrenia Working Groups of the Psychiatric Genomics Consortium) (Marshall et al., 2017; Bray and O’Donovan, 2018). It is well known that 20%–30% of people with a 22q11.2 deletion have schizophrenia (Murphy et al., 1999), and the prevalence of obesity and T2DM is reported to be greater than normal in 22q11.2 deletion syndrome (Voll et al., 2017). A partial 22q11.2 deletion that includes several genes related to the neuropsychiatric phenotype, catechol-O-methyltransferase (COMT) (Xiu et al., 2015) and thioredoxin reductase 2 (TXNRD2) (Kariž et al., 2015), is associated with the onset of T2DM. Of 8 top candidate genes for schizophrenia affected by CNVs (Luo et al., 2014), only B-cell CLL/lymphoma 9 (BCL9) (1q21.1), which is required in the Wnt signaling pathway, was reported to be associated with T2DM (Anderson et al., 2015) or schizophrenia (Li et al., 2011), although there are not enough studies on the relationship between CNVs and T2DM, unlike schizophrenia. Prabhjan et al. (2016) reported 24 CNV genes in patients with T2DM, and DLG associated protein 1 (DLGAP1), a scaffold protein of the postsynaptic density that is related to post-synapse neurotransmission of glutamate, is suspected to be genetically and functionally related to schizophrenia (Kirov et al. 2012; Rasmussen et al. 2017).
Common Functional Cascade in Schizophrenia and T2DM

Rho GTPase—Disturbances in synaptic connectivity during perinatal and adolescent periods underlie the pathophysiology of schizophrenia (McGlashan and Hoffman, 2000). Postmortem brain studies of individuals with schizophrenia have reported reduced dendritic spine density in the cerebral neocortex (Glantz and Lewis, 2000; Konopaske et al., 2014). These dendritic spine abnormalities are likely the result of disturbances in the molecular mechanisms that contribute to spine formation, pruning, and/or maintenance (Glausier and Lewis, 2013). Dendritic spine morphogenesis is regulated through cytoskeletal actin, which is concentrated highly in the spines (Fischer et al., 1998).

The Rho family of small GTPases (Rho GTPases), which includes Cdc42, Rac1, and RhoA, is a critical regulator of actin cytoskeleton dynamics and organization in the spines (Hall, 1998). The activation of Rho GTPases is mediated by specific guanine-nucleotide exchange factors (GEFs) that catalyze the exchange of bound GDP (inactive state) for bound GTP (active state) (Van Aelst and D’Souza-Schorey, 1997). Several Rho GEFs that localize to dendritic spines play important roles in dendritic spine morphogenesis by modulating the activity of Rho GTPases (Xie et al., 2007).

ARHGEF11 is a specific GEF for RhoA (Rumenapp et al., 1999). ARHGEF11 variants are associated with a higher risk for the onset of schizophrenia in a Japanese population (Mizuki et al., 2014). ARHGEF11 interacts and colocalizes with synapse marker postsynaptic density protein 95 (PSD-95) at synapse sites and negatively regulates the formation of dendritic spines in cortical primary neurons (Mizuki et al., 2016). In a yeast 2-hybrid screen, ARHGEF11 interacts with disrupted-in-schizophrenia 1 (DISC1) (Miller et al., 2003). DISC1 directly interacts with PSD-95 and kalirin-7, a GEF for Rac1, and blocks access of kalirin-7 to Rac1. This binding is released by N-methyl-D-aspartate (NMDA) receptor activation, allowing free access of kalirin-7 to Rac1 and leading to the resultant activation of Rac1 and spine enlargement (Hayashitakagi et al., 2010). On the other hand, platelet-activating factor acetylhydrolase 1B1 (LIS1), one of the major binding partners of DISC1, is associated with RhoA activity (Kholmanskikh et al., 2003). Raploincisficiency in LIS1 has also been shown to reduce spine density, while downregulation of RhoA rescued spine mobility (Sudarov et al., 2013). DISC1 may also regulate the access of ARHGEF11 to RhoA, resulting in spine shrinkage. Regulation of Rho GTPases by DISC1 may be crucial for proper maintenance of the dendritic spine (Tropea et al., 2018). DISC1 (Ma et al., 2018; Xu et al., 2018) and kalirin (Kushima et al., 2012) are also reported to be associated with schizophrenia. Though DISC1 is not considered a common risk gene for schizophrenia by GWAS, DISC1 may play critical roles as a pathological mediator in a wide range of psychiatric disorders (Niwa et al., 2016).

Dysfunction of insulin release from pancreatic islet β-cells is considered to be one of the causal factors in the etiology of T2DM. Rac1 is particularly important for glucose-stimulated insulin secretion (Wang and Thurmond, 2009). In contrast, RhoA expression is increased in β-cells under diabetic conditions, and Rho/Rho-kinase activation is involved in the suppression of insulin biosynthesis (Nakamura et al., 2006). Thus, insulin release from pancreatic islet β-cells could be determined by the resulting balance between RhoA and Rac1 activities. These findings suggest that Rho GTPase signaling affects not only the dendritic spine structure but also a number of cellular processes, including insulin release from pancreatic islet β-cells, and that aberrations in Rho GTPase signaling, including its activation by GEFs, could therefore contribute to the comorbidity of schizophrenia and T2DM (Figure 1).

Wnt/β-Catenin

Wnts are secreted glycoproteins known as extracellular ligands. Wnt/β-catenin signaling (canonical pathway) is a critical and well-studied pathway (MacDonald et al., 2009). In the absence of Wnt ligands, cytoplasmic β-catenin protein is tightly regulated at a low level by casein kinase 1 (CK1)-mediated phosphorylation and the regulatory adenomatous polyposis coli (APC)/axin/glycogen synthase kinase-3 (GSK-3) complex, leading to its ubiquitination and subsequent proteasomal degradation (Gao et al., 2014). In an activated state, Wnt signaling promotes destruction of APC/axin/GSK-3β complex components and inhibition of β-catenin degradation. β-Catenin accumulates in the cytoplasm and eventually translocates into the nucleus, where it binds with T-cell factor/lymphoid enhancer factor (TCF/LEF) family members and induces the transcription of target genes (Shang et al., 2017). The Wnt signaling pathway is crucial for regulating diverse biological processes such as embryonic development, organ formation, and cell proliferation. This pathway plays an important role in the pathophysiology of T2DM and has been shown to be critical for the development of the pancreas and islets during embryonic growth (Papadopoulou and Edlund, 2005). The Wnt/β-catenin pathway also plays a role in neuronal development (Brafman and Willert, 2017).

TCF7L2, also called TCF4, is one of the TCF/LEF family members. The TCF7L2 gene encodes a high mobility (HM) box that plays an important role in the downstream Wnt/β-catenin signal pathway (Hansson et al., 2010). Functionally, TCF7L2 is critical for β-cell proliferation and survival as well as insulin production and secretion (Liu and Habener, 2010) and is a key regulator of insulin and proinsulin synthesis and processing (Zhou et al., 2014). Although studies of TCF7L2 in brain development and pathologies have been relatively scarce, evidence from animal studies strongly implicates TCF7L2-dependent transcription in the development of changes in the volume of cortical areas, thalamo-cortical dysconnectivity, and white matter microstructural alterations (Bem et al., 2019). TCF7L2 also regulates synaptic plasticity (Kennedy et al., 2016). Therefore, TCF7L2 may contribute to the comorbidity between schizophrenia and T2DM.

DISC1 also regulates the stability of Wnt/β-catenin signaling by an interaction with GSK3β and acts through this pathway to regulate neural progenitor proliferation and modulate mental homeostasis (Mao et al., 2009). Disheveled-axin domain-containing 1 (DIXDC1), a direct interacting partner of DISC1, contributes to psychiatric pathogenesis by regulating dendritic spine and glutamatergic synapse density downstream of Wnt/β-catenin signaling (Martin et al., 2018).

Akt/GSK3

GSK3 plays several roles in differentiation and development, intracellular trafficking, apoptosis, and regulation of gene transcription (Emamian, 2012). Some studies suggest that GSK3 in the brain could modulate synaptic plasticity (Emamian, 2012). GSK-3β is a key player of Wnt signaling pathways (Freyberg et al., 2010). GSK3 is a molecule immediately downstream to Akt, a serine/threonine kinase (Freyberg et al., 2010). GSK3 and Akt are serine threonine kinases that were initially identified as...
playing a role in regulating the activity of glycogen synthesis in response to insulin receptor stimulation (Beaulieu, 2012). Insulin signals through the tyrosine kinase activity of its receptor to activate Akt through the phosphatidylinositol 3-kinase pathway. Akt phosphorylates GSK-3 and inactivates it (Lovestone et al., 2007). Of interest, DISC1 regulates pancreatic β-cell function, decreases β-cell proliferation, and promotes apoptosis and glucose intolerance in transgenic mice via regulation of GSK3β (Jurczyk et al., 2016).

GSK3 has also been implicated in the pathogenesis of schizophrenia and the actions of neurotransmission of dopamine (Kaidanovich-Beilin et al., 2012). GSK3 is a major downstream regulator of dopamine receptor D2 (DRD2), which is targeted by most antipsychotics. Besides the canonical G protein-dependent cAMP-protein kinase A signaling pathway, the non-canonical DRD2 transduction pathway is the G protein-independent Akt/GSK3 pathway (Beaulieu et al., 2011). Activation of DRD2 by dopamine facilitates the arrestin 2/protein phosphatase 2A/Akt complex and dephosphorylates and inactivates Akt, followed by dephosphorylation (activation) of GSK3 (Beaulieu et al., 2011). Chronic administration of a dopamine agonist, such as amphetamine or apomorphine, also leads to increased

---

Figure 1. Summary of plausible shared mechanisms for the pathogenetic association between schizophrenia and type 2 diabetes mellitus (T2DM). (A) Schematic representation of Rho family of small GTPases (Rho GTPases) signaling cascades involved in synaptic plasticity. Rho guanine-nucleotide exchange factor 11 (ARHGEF11) interacts and colocalizes with synapse marker postsynaptic density protein 95 (PSD-95) at synapse sites and negatively regulated the formation of dendritic spines in cortical primary neurons (Mizuki et al., 2016). Disrupted-in-schizophrenia 1 (DISC1) directly interacts with PSD-95 and kalirin-7, a GEF for Rac1, and blocks access of kalirin-7 to Rac1. This binding is released by N-methyl-D-aspartate (NMDA) receptor activation, allowing free access of kalirin-7 to Rac1 and leading to the resultant activation of Rac1 and spine enlargement (Hayashi-Takagi et al., 2010). (B) The role of Rho GTPase in pancreatic β cells. Rac1 is particularly important for glucose-stimulated insulin secretion (Wang and Thurmond, 2009). In contrast, RhoA expression is increased in β-cells under diabetic conditions, and Rho/Rho-kinase activation is involved in the suppression of insulin biosynthesis (Nakamura et al., 2006). Insulin release from pancreatic islet β-cells could be determined by the resulting balance of Rho GTPase signaling. Illustrating this schematic figure, we referenced figures of Hayashi-Takagi et al., 2010 and Wang et al., 2009.
Inhibitory phosphorylation of Akt and increased activation of GSK3β (Beaulieu et al., 2011). On the other hand, antipsychotics are able to increase Akt activation (Emamian et al., 2004; Takaki et al., 2018). These data establish a strong relationship between dopamine levels and Akt/GSK3β signaling (Singh, 2013). Akt and GSK-3 may be modulated by DISC1 with indirect and direct interactions, respectively (Dahoun et al., 2017). The Akt/GSK-3 pathway may be responsible for the co-occurrence of T2DM and schizophrenia (Lin and Shuldiner, 2010).

Multiple genetic, functional, and animal studies have shown that COMT is significantly associated with schizophrenia (Luo et al., 2014). COMT is a prime candidate for ameliorating the cognitive dysfunction of schizophrenia (Tunbridge et al., 2006). COMT polymorphism is also associated with hyperglycemia and hemoglobin A1C in T2DM (Hall et al., 2016). Furthermore, COMT is related to the Akt/GSK3 cascade. The COMT Val108/158Met genotype is related to Akt phosphorylation, and information on functional interactions between COMT and Akt may provide novel insights into the pathogenesis of schizophrenia (Sei et al., 2010).

Increasing evidence reveals regulatory interactions between dopamine and the central renin-angiotensin system (Oh and Fan, 2019). ACE catalyzes the conversion of angiotensin I to the active hypertensive peptide angiotensin II. Angiotensin II induces dopamine release in mesolimbic dopaminergic neurons (Rodriguez et al., 2020). Although several studies reported that ACE activity is inconsistent in patients with schizophrenia, higher ACE activity is associated with cognitive dysfunction in patients with schizophrenia (Rodriguez et al., 2020). Because angiotensin II increases hepatic glucose production and decreases insulin sensitivity, ACE inhibitor and angiotensin receptor blockers are reported to reduce the occurrence of T2DM (Gillespie et al., 2005).

**Common Mechanisms in Schizophrenia and T2DM**

**Inflammation Abnormality**—Inflammation is a necessary response to infection, harmful chemicals, and tissue damage (Muller, 2018). Inflammation comes at the cost of a transient decline in tissue function, which in turn contributes to altering the homeostasis and becomes the pathogenesis of diseases (Medzhitov, 2010). The long-term effects of inflammatory mediators induce neuropsychiatric disease in the brain as well as metabolic disease in the pancreas (Bauer and Teixeira, 2019).

The origins of inflammatory and immune activation in schizophrenia include (1) genetic predisposition; (2) prenatal exposure to infections (Brown and Derkits, 2010); maternal inflammation during pregnancy (Canetta et al., 2014), and obstetric complications (Cannon et al., 2002); (3) gastrointestinal permeability and the gut microbiome (Severance et al., 2016); (4) psychological trauma (Popovic et al., 2019; Stilo and Murray, 2019) and other environmental exposures such as a low level of serum vitamin D (Davis et al., 2016) and substance use (Miller et al., 2018); and (5) abnormalities in brain insulin action (Agarwal et al., 2020). These inflammations affect the development and activity of microglial cells, which work in the primary inflammations in the central nervous system (Howes and McCutcheon, 2017). Findings from the current meta-analysis seem to support elevated levels of pro-inflammatory marker cytokines, such as interleukin-6 (IL-6), IL-1β, and tumor necrosis factor A (TNF-A), in the blood and cerebrospinal fluid of patients with schizophrenia (Goldsmit et al., 2016; Capuzzi et al., 2017). Inflammatory markers have been found to be increased in the first episode of schizophrenia, and manifested alterations in the severity and resistance to treatment in various stages of the illness (Fineberg and Ellman, 2013; Upthegrove et al., 2014; Capuzzi et al., 2017).

Furthermore, these inflammatory markers are associated with negative symptoms, indicating loss of brain matter and cognitive impairment in patients with schizophrenia (Garcia-Rizo et al., 2012; Fillman et al., 2013; Meyer, 2013).

Low-grade inflammation has also been described as a risk factor for future development of T2DM. Many studies reported increased levels of pro-inflammatory markers, such as IL-6, IL-1β, and TNF-A, which are predictive components in patients with T2DM (Rehman and Akash, 2016). Pediatric studies, which have the advantage of not being influenced by other diseases, medications, or active tobacco smoking, have demonstrated that IL-1β, IL-6, TNF-A, and other markers are increased in insulin resistance (Reinehr, 2019). Thus, pro-inflammatory mediators could promote insulin resistance and β-cell failure, ultimately resulting in the development of T2DM. Psychological stress can be considered to have a significant role in the onset and progression of diabetes (Afrisham et al., 2019). Although the liver and adipose tissue are important sites for the activation of inflammation pathways, chronic stress directly activates the innate immune system, which, in turn, activates the production of IL-6 and other cytokines (Pickup, 2004). With a genetic predisposition, subsequent stress contributes a vulnerability factor for inflammation-associated schizophrenia. Multiple genome-wide association studies have shown that the major histocompatibility complex on chromosome 6p, which is known to play a key role in the immune system, is an important region for allelic association in schizophrenia (Ripke, 2014). In particular, alleles of complement C4 within the human leukocyte antigen were found to be associated with schizophrenia, and C4 promotes synaptic elimination (Sekar et al., 2016). C4 levels also correlate with body mass index (Copenhaver et al., 2019). IL-1β, IL-6, and IL6R genes were associated with schizophrenia in a meta-analysis (Hudson and Miller, 2018) and an association study (Kapelski et al., 2015). Variants in IL1B, IL6, and other cytokine genes were associated with T2DM in multiple studies (Achyut et al., 2007; Arora et al., 2011; Banerjee and Saxena, 2014). An altered immune system and inflammatory components induced by chronic stress were associated with the molecular mechanisms of diabetes in schizophrenia (van Beveren et al., 2014; Ward and Druss, 2015).

Thus, inflammation may be a common underlying mechanism for schizophrenia and diabetes mellitus, which are highly comorbid with each other (Khandaker et al., 2017).

**Oxidative Stress**

Oxidative stress is defined as an imbalance between the production of reactive oxygen species and their elimination by a protective mechanism (antioxidant system), which can lead to chronic inflammation (Hussain et al., 2016). Oxidative stress is harmful because excess reactive oxygen species attacks biological molecules such as proteins and DNA (Yoshikawa and Naito, 2002). An accumulation of oxidative damage to biological molecules is involved in the pathogenesis of various diseases, including metabolic diseases, diabetes complications, and neurodegenerative disorders (Emiliani et al., 2014). Multiple lines of evidence have identified increased oxidative stress in patients with schizophrenia (Koga et al., 2016). Most studies examined markers of oxidative status in the blood, such as endogenous antioxidants glutathione (GSH) (Barron et al., 2017). A recent extensive review found that peripheral markers of GSH were consistently decreased but found equivocal results for other antioxidants such as superoxide dismutase and catalase...
Figure 2. Mechanisms that underlie the association between schizophrenia and type 2 diabetes mellitus (T2DM). The mechanisms of the increasing prevalence of T2DM in patients with schizophrenia are multifactorial. Poor diet and sedentary lifestyle are included in the traditional risk factors. Iatrogenic risk during treatment with antipsychotics is included in risk factors unique to schizophrenia (Ward and Druss, 2015). Accumulating evidence suggests shared genetic susceptibility and biological common pathway of both schizophrenia and T2DM.

(Koga et al., 2016). Genetic studies have shown associations between oxidative stress gene polymorphisms and schizophrenia, including genetic variations in a subunit of GSH cysteine ligase, the enzyme responsible for GSH synthesis, and several glutathione S-transferases (GST), utilizing GSH as a co-factor (Gysin et al., 2007; Gravina et al., 2011). Meta-analysis studies have found the association of the most important genes of the GST family, GSTM1 and GSTT1 variants, with T2DM (Tang et al., 2013; Zhang et al., 2013a). However, unlike genetic association studies, the available GWASs have not provided convincing evidence for an oxidative stress–related genetic predisposition to schizophrenia (Maas et al., 2017).

PON1 is a candidate for a gene that overlaps schizophrenia and T2DM. PON1 enzyme is known to have a protective effect against oxidative stress (Menini and Gugliucci, 2014; Bigagli and Lodovici, 2019). In this context, PON1 activity is inversely associated with inflammatory responses. Drug-naïve first-episode patients with schizophrenia show an inverse relationship between decreased activity of the enzyme PON1 and increased cytokine levels, including IL-6, IL-4, and IL-10 (Brinholi et al., 2015). PON1 activity is also decreased in T2DM and related to β-cell function (Meneses et al., 2019).

MTHFR is a key enzyme for 1-carbon metabolism and DNA methylation. MTHFR polymorphisms (C677T and A1298C) are related to enzymatic activity, and an approximately 20% reduction in MTHFR enzyme activity is shown in patients with schizophrenia (Wan et al., 2018). Interestingly, these polymorphisms are frequently reported in the onset of T2DM and diabetic nephropathy (Mitraou et al., 2007).

HPA Axis Dysfunction

The HPA axis, a neuroendocrine system, plays a fundamental role in the maintenance of reactions to stress and affects the physiologic adaptive reactions of the organism to stressors (Nicolaides et al., 2015). HPA is involved in the homeostasis of metabolic, cardiovascular, and reproductive systems, as well as the immune system (van den Brink et al., 2018). The central stress system triggers the synthesis and secretion of corticotropin-releasing hormone (CRH) in the paraventricular nuclei of the hypothalamus (Chrousos, 1995). Through the hypophysial portal system, CRH reaches the anterior pituitary gland and releases adrenocorticotropic hormone (ACTH) into the systemic circulation. On binding to the glucocorticoid receptors of the adrenocortical cells, ACTH subsequently induces glucocorticoid synthesis and secretion, which control CRH and ACTH release via a negative feedback loop (van den Brink et al., 2018). Consequently, the blood glucocorticoid concentration is increased by the stress reaction. Glucocorticoids are steroid hormones that regulate multiple aspects of glucose homeostasis. Glucocorticoids promote gluconeogenesis in the liver by induction of gluconeogenesis enzymes and decrease glucose uptake and utilization by antagonizing the insulin response in skeletal muscle and adipose tissue (Chiodini et al., 2007). Therefore, excess or long-lasting (chronic) glucocorticoid exposure causes hyperglycemia and insulin resistance. In patients with T2DM, glucocorticoid secretion has been suggested to be a possible link between insulin resistance and the features of metabolic syndrome (Chiodini et al., 2007).

Epidemiological studies have revealed that HPA activity plays a role in the pathophysiology of schizophrenia. Proinflammatory cytokines such as IL-1, IL-6, or TNF are also involved in activating the HPA axis (Chrousos, 1995; Meyer, 2013). Although there are contradictory reports (Ciufolini et al., 2014), schizophrenia is associated with elevated baseline and challenge-induced HPA activity (Walker et al., 2008). Furthermore, control of the HPA axis was also impaired in drug-naïve and first-episode patients with schizophrenia (Ryan et al., 2004), and baseline cortisol levels are higher in prodromal (clinically high risk) patients (Walker et al., 2013). However, these findings are not universal, and there is limited
agreement about elevations in glucocorticoids (Bradley and Dinan, 2010).

Other Endocrine Systems (Prolactin)

The prolactin (PRL) pathway may contribute to the comorbidity of schizophrenia and T2DM (Gragnoli et al., 2016). PRL lies on locus 6p22.3, which is strongly associated with T2DM in the GWAS replication study (Lu et al., 2012). PRL plays a role in regulation of beta-cell mass (Nielsen et al., 2001), islet regeneration and proliferation (Nyblom et al., 2009), and insulin secretion (Sorensen and Breiæ, 2009). Low PRL levels are related to a higher T2DM risk in both sexes (Balbach et al., 2013). On the other hand, higher PRL levels were associated with lower glucose levels and higher insulin sensitivity (Wagner et al., 2014).

PRL levels are also associated with schizophrenia. First-episode drug-naïve male schizophrenia patients have serum PRL levels 3 times higher than healthy male controls (Albayrak et al., 2014). It has also been shown that the PRL level is negatively associated with the severity of positive psychosis symptoms in drug-naïve male patients with schizophrenia (Ramsey et al., 2013). Furthermore, PRL polymorphism is associated with schizophrenia, especially in male patients (Rybakowski et al., 2012). Although increased or decreased PRL levels have not been found consistently across studies or by gender difference (Rajkumar, 2014), PRL dysfunction may sustain disrupted mental development and T2DM-related metabolism.

Other candidate genes, PRL-releasing hormone receptor (PRLRH), PRL receptor (PRLR), oxytocin (OXT), oxytocin receptor (OXTR), and NPY, may also correlate with the PRL pathway and contribute to schizophrenia and T2DM. However, genetic data on PRLRH, PRLR, OXT, OXTR, and NPY in human T2DM and schizophrenia patients are scarce (Postolache et al., 2019).

CONCLUSION

We summarized the genetics and functional mechanisms underlying the comorbidity of schizophrenia and T2DM (Figure 2). Even when genetic analyses are performed on a relatively large number of comorbid patients, the results are sometimes inconsistent, and susceptibility genes may also have only a low or moderate risk to the onset of both. Genetic association studies have revealed the number of common risk variants underlying diseases, but these variants explain only a proportion of heritability. Among the reasons for the complexity in this field are suspected to be the following: (1) the heterogeneity of schizophrenia; (2) many environmental factors, such as lifestyle and vulnerability to life events, which are related to genetic factors; and (3) both genetic and environmental factors that affect common mechanisms in schizophrenia and T2DM, such as abnormal inflammation, oxidative stress, and HPA axis dysfunction. It is very difficult to distinguish purely environmental factors from purely genetic factors. A new approach is to estimate environmental factors statistically compensated by digitized intermediate phenotypes directly related to genetic factors, such as cognitive function, structural or functional magnetic resonance imaging analysis, and cerebral blood flow.

On the other hand, based on many genetic and epidemiological studies, the comorbidity of schizophrenia and T2DM is established, and it is probably safe to assume that common cascades and mechanisms suspected from common genes’ functions in the brain or pancreas are related to the onset of schizophrenia and T2DM. At the point of preemptive medicine, genetic and epidemiological information will be used in making decisions for the prevention and treatment of schizophrenia and T2DM. Though introduction of new medications or supplements that are effective in these cascades and mechanisms may be expected, 1 target point may not be adequate because each common cascade and mechanism is also closely linked. In the future, in addition to more comprehensive whole genome and epigenome analyses of schizophrenia and T2DM, a more precise approach such as familial and rare gene analyses of CNVs of comorbid patients, further subdivision of the diagnoses of schizophrenia, and the following basic functional research may eliminate these difficulties and clarify the treatment target for patients with the same phenotype but different causes.

Acknowledgments

The authors thank the Zikei Institute of Psychiatry (Okayama, Japan).

Interest Statement

Y.Y. has received honoraria for speaking at educational events sponsored by Novartis and Dainippon Sumitomo. N.Y. has received unrestricted research funding from Daiichi Sankyo, Eisai, Pfizer, Otsuka, Astellas, and Merck Sharp & Dohme, which was deposited into research accounts at Okayama University. N.Y. has also received honoraria for his participation as a speaker at educational events from UCB Japan, Tsumura, Pfizer, Dainippon-Sumitomo, Daichi Sankyo, Merck Sharp & Dohme, Pfizer, Eisai, Meiji-Seika, and Mochida. M.T. has received honoraria for his participation as a speaker at educational events sponsored by Daiichi Sankyo, Takeda, Tsumura, Otsuka, and Dainippon Sumitomo. S.S. has received unrestricted research funding from Eli Lilly, which was deposited into research accounts at Okayama University Hospital. S.S. has received honoraria for his participation as a speaker at an educational event sponsored by Otsuka and Meiji-Seika. Y.M. has received honoraria for his participation as a speaker at educational events sponsored by Otsuka and Dainippon Sumitomo. N.H. received honoraria for his participation as a speaker at educational events sponsored by Otsuka, Eisai, and Nippon Shinyaku. Y.O. reports no additional financial or other relationship relevant to this article.

References

Achuyt BR, Srivastava A, Bhattacharya S, Mittal B (2007) Genetic association of interleukin-1beta (-511C/T) and interleukin-1 receptor antagonist (86 bp repeat) polymorphisms with Type 2 diabetes mellitus in North Indians. Clin Chim Acta 377:163–169.

Afrisham R, Paknejad M, Soliemanifar O, Sadegh-Nejadi S, Meshkini R, Ashtary-Larky D (2019) The influence of psychological stress on the initiation and progression of diabetes and cancer. Int J Endocrinol Metab 17:e67400.

Agarwal SM, Caravaggio F, Costa-Dookhan KA, Castellani L, Kowalczuk C, Asgariroozbehani R, Graff-Guerrero A, Hahn M (2020) Brain insulin action in schizophrenia: something borrowed and something new. Neuropsychopharmacology 163:107633.

Albayrak Y, Beyazıyüz M, Beyazıyüz E, Kugloğlu M (2014) Increased serum prolactin levels in drug-naïve first-episode male patients with schizophrenia. Nord J Psychiatry 68:341–346.
Canetta S, Sourander A, Surcel HM, Hinkka-Yli-Salomäki S, Levisská J, Kellendonk C, McKeague IW, Brown AS (2014) Elevated maternal C-reactive protein and increased risk of schizophrenia in a national birth cohort. Am J Psychiatry 171:960-968.

Cannon M, Jones PB, Murray RM (2002) Obstetric complications and schizophrenia: historical and meta-analytic review. Am J Psychiatry 159:1080-1092.

Capuzzi E, Bartoli F, Crocamo C, Clerici M, Carrà G (2017) Acute variations of cytokine levels after antipsychotic treatment in drug-naïve subjects with a first-episode psychosis: a meta-analysis. Neurosci Biobehav Rev 77:122-128.

Chen J, Cao F, Liu L, Wang L, Chen X (2015) Genetic studies of schizophrenia: an update. Neurosci Bull 31:87-98.

Chioldini I, Adda G, Scillitani A, Coletti F, Morelli V, Di Lembo S, Epaminonda P, Masserini B, Beck-Peccoz P, Orsi E, Ambrosi B, Arosio M (2007) Cortisol secretion in patients with type 2 diabetes: relationship with chronic complications. Diabetes Care 30:83-88.

Chrousos GP (1995) The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 332:1351-1362.

Chung J, Miller BJ (2020) Meta-analysis of comorbid diabetes and family history of diabetes in non-affective psychosis. Schizophr Res 216:41-47.

Ciufolini S, Dazzan P, Kempton MJ, Pariante C, Mondelli V (2014) HPA axis response to social stress is attenuated in schizophrenia but normal in depression: evidence from a meta-analysis of existing studies. Neurosci Biobehav Rev 47:359-368.

Copenhaver M, Yu CY, Hoffman RP (2019) Complement components, C3 and C4, and the metabolic syndrome. Curr Diabetes Rev 15:44-48.

Crump C, Winkleby MA, Sundquist K, Sundquist J (2013) Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study. Am J Psychiatry 170:324-333.

Dahoun T, Trossbach SV, Brandon NJ, Korth C, Howes OD (2017) The impact of Disrupted-in-Schizophrenia 1 (DISC1) on the dopaminergic system: a systematic review. Transl Psychiatry 7:e1015.

Das SK, Elbein SC (2006) The genetic basis of type 2 diabetes. CellScience 2:100-131.

Das SK, Elbein SC (2007) The search for type 2 diabetes susceptibility loci: the chromosome 1q story. Curr Diab Rep 7:154-164.

Davis J, Eyre H, Jacka FN, Dodd S, Dean O, McEwen S, Debnath M, McGrath J, Maes M, Amminger P, McGorry PD, Pantelis C, Berk M (2016) A review of vulnerability and risks for schizophrenia: beyond the two hit hypothesis. Neurosci Biobehav Rev 65:185-194.

Demjaha A, MacCabe JH, Murray RM (2012) How genes and environmental factors determine the different neurodevelopmental trajectories of schizophrenia and bipolar disorder. Schizophr Bull 38:209-214.

Dickerson F, Rubalaca E, Viscidi R, Yang S, Stallings C, Sullens A, Ongini A, Leister F, Volken R (2008) Polymorphisms in human endogenous retrovirus K-18 and risk of type 2 diabetes in individuals with schizophrenia. Schizophr Res 104:121-126.

Emamian ES (2012) AKT/GSK3 signaling pathway and schizophrenia. Front Mol Neurosci 5:33.

Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA (2004) Convergent evidence for impaired AKT-GSK3beta signaling in schizophrenia. Nat Genet 36:131-137.

Emilianie FE, Sedlak TW, Sawa A (2014) Oxidative stress and schizophrenia: recent breakthroughs from an old story. Curr Opin Psychiatry 27:185-190.
Fillman SG, Cloonan N, Catts VS, Miller LC, Wong J, McCrossin T, Cairns M, Weickert CS (2013) Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia. Mol Psychiatry 18:206–214.

Fineberg AM, Ellman LM (2013) Inflammatory cytokines and neurological and neurocognitive alterations in the course of schizophrenia. Biol Psychiatry 73:951–966.

Fischer M, Kaech S, Knutti D, Matus A (1998) Rapid actin-based plasticity in dendritic spines. Neuron 20:847–854.

Foley DL, Mackinnon A, Morgan VA, Watts GF, McGrath JJ, Fischer M, Kaech S, Knutti D, Matus A (1998) Rapid actin-based plasticity in dendritic spines. Neuron 20:847–854.

Freyberg Z, Ferrando SJ, Javitch JA (2010) Roles of the Akt/GSK-3 by-β-catenin signaling.

Garcia-Rizo C, Fernandez-Egea E, Oliveira C, Justicia A, Ber-β-catenin signaling. Am J Psychiatry 167:388–396.

Gao C, Xiao G, Hu J (2014) Regulation of Wnt/β-catenin signaling by posttranslational modifications. Cell Biosci 4:13.

García-Rizo C, Fernandez-Egea E, Oliveira C, Justicia A, Bernardino M, Kirkpatrick B (2012) Inflammatory markers in antipsychotic-naive patients with nonaffective psychosis and deficit vs. nondeficit features. Psychiatry Res 198:212–215.

Gillespie EL, White CM, Kardas M, Lindberg M, Coleman CI (2005) The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care 28:2261–2266.

Glantz LA, Lewis DA (2000) Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch Gen Psychiatry 57:65–73.

Glausier JR, Lewis DA (2013) Dendritic spine pathology in schizophrenia. Neuroscience 251:90–107.

Goldsmith DR, Rapaport MH, Miller BJ (2016) A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry 21:1696–1709.

Gough SC, O’Donovan MC (2005) Clustering of metabolic comorbidity in schizophrenia: a genetic contribution? J Psychopharmacol 19:47–55.

Gragnoli C (2010) PSMD9 gene in the NIDDM2 locus is linked to type 2 diabetes in Italians. J Cell Physiol 222:265–267.

Gragnoli C, Reeves GM, Reazer J, Postolache TT (2016) Dopamine-6-cell function via glycogen synthase kinase-3β. Front Mol Neurosci 5:48.

Greco RJ, Hidalgo K, Arai N, Ikeda K, Yoshikawa T, Sora I, Ikeda K, Yoshikawa T (2003) Association between a novel polymorphism in the promoter region of the neuropeptide Y gene and schizophrenia in humans. Neurosci Lett 347:202–204.

Hall KT, Jablonski KA, Chen L, Harden M, Tolkin BR, Kaptchuk TJ, Bray GA, Rizker PM, Florez JC, Mukamal KJ, Chasan- Diabetes Prevention Program Research Group (2016) Catechol-O-methyltransferase association with hemoglobin A1c. Metabolism 65:961–967.

Hansson O, Zhou Y, Renström E, Osmark P (2010) Molecular function of TCF7L2: Consequences of TCF7L2 splicing for molecular function and risk for type 2 diabetes. Curr Diab Rep 10:444–451.

Hayashi-Takagi A, Takaki M, Graziane N, Seshadri S, Murdoch H, Dunlop AJ, Makino Y, Seshadri AJ, Ishizuka K, Srivastava DP, Xie Z, Baraban JM, Houslay MD, Tomoda T, Brandon NJ, Kaniya A, Yan Z, Penez S, Sawa A (2010) Disrupted-in-Schizophrenia 1 (DISC1) regulates spines of the glutamate synapse via Rac1. Nat Neurosci 13:327–332.

Hendriks LA, Sethupathy P, Junkins HA, Rams EM, Mehta JP, Collins FS, Manolio TA (2009) Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci U S A 106:9362–9367.

Howes OD, McCutcheon R (2017) Inflammation and the neural diathesis-stress hypothesis of schizophrenia: a reconceptualization. Transl Psychiatry 7:e1024.

Hudson ZD, Miller BJ (2018) Meta-analysis of cytokine and chemokine genes in schizophrenia. Clin Schizophr Relat Psychoses 12:121–129.

Hussain T, Tan B, Yn Y, Blachier F, Tossou MC, Rahn N (2016) Oxidative stress and inflammation: what polyphenols can do for us? Oxid Med Cell Longev 2016:743279.

Ikotawa M, Arai M, Kato S, Ogata Y, Furukawa A, Haga S, Ujike H, Sora I, Ikeda K, Yoshikawa T (2003) Association between a novel polymorphism in the promoter region of the neuropeptide Y gene and schizophrenia in humans. Neurosci Lett 347:202–204.

Jackson M, Song W, Liu MY, Jin L, Dykes-Hoberg M, Lin CI, Bowers WJ, Federoff HJ, Sterrweis PC, Rothstein JD (2001) Modulation of the neuronal glutamate transporter EAAT4 by two interacting proteins. Nature 410:89–93.

Jurczuk A, Nowosielska A, Przewozniak A, Aryee KE, Dilorio P, Blodgett D, Yang C, Campbell-Thompson M, Atkinson M, Shultz L, Rittenhouse A, Harlan D, Greiner D, Bortell R (2016) Beyond the brain: disrupted in schizophrenia 1 regulates pancreatic β-cell function via glycogen synthase kinase-3β. FASEB J 30:983–993.

Juster RP, Russell JJ, Almeida D, Picard M (2016) Allostatic load and comorbidities: a mitochondrial, epigenetic, and evolutionary perspective. Dev Psychopathol 28:1117–1146.

Kaidanovich-Beilin O, Beaulieu JM, Jope RS, Woodgett JR (2012) Neurological functions of the masterswitch protein kinase gsk-3. Front Mol Neurosci 5:48.

Kajio Y, Kondo K, Saito T, Iwayama Y, Aleksic B, Yamada K, Toyota T, Hattori E, Ujike H, Inada T, Kunugi H, Kato T, Yoshikawa T, Ozaki N, Ikeda M, Iwata N (2014) Genetic association study between the detected risk variants based upon type II diabetes GWAS and psychotic disorders in the Japanese population. J Hum Genet 59:54–56.

Kapelski P, Skibinska M, Maciukiewicz M, Wilkosc M, Frydecka D, Groszewski A, Narozna B, Dmitrzak-Weglarz M, Czerski P, Pawlak J, Rajewska-Rager A, Leszczynska-Rodziewicz A, Slopien A, Zaremba D, Twarowska-Hauser J (2016) Association of two interacting proteins. Nature 410:89–93.

Kariž S, Manko S, Petrović D, Skibinska M, Maciukiewicz M, Wilkosc M, Frydecka D, Groszewski A, Narozna B, Dmitrzak-Weglarz M, Czerski P, Pawlak J, Rajewska-Rager A, Leszczynska-Rodziewicz A, Slopien A, Zaremba D, Twarowska-Hauser J (2016) Association of two interacting proteins. Nature 410:89–93.
Kennedy AJ, Rahm EJ, Paulukaitis BS, Savell KE, Kordasiewicz HB, Wang J, Lewis JW, Posey J, Strange SK, Guzman-Karlsson MC, Phillips SE, Decker K, Motley ST, Swayne EE, Ecker DJ, Michael TP, Day JJ, Sweatt JD (2016) Tcf4 regulates synaptic plasticity, DNA methylation, and memory function. Cell Rep 16:2666–2685.

Khandaker GM, Dantzer R, Jones PB (2017) Immunopsychiatry: important facts. Psychol Med 47:2229–2237.

Kholmansikhh SS, Dobrin JS, Wynshaw-Boris A, Letourneau PC, Ross ME (2003) Disregulated RhoGTPases and actin cytoskeleton contribute to the migration defect in Lis1-deficient neurons. J Neurosci 23:8673–8681.

Kirov G, et al. (2012) De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia. Mol Psychiatry 17:142–153.

Koga M, Serritella AV, Sawa A, Sedlak TW (2016) Implications for reactive oxygen species in schizophrenia pathogenesis. Schizophr Res 176:52–71.

Konopaske GT, Lange N, Coyle JT, Benes FM (2014) Prefrontal cortex abnormalities of postsynaptic signalling complexes in the skeleton contribute to the migration defect in Lis1-deficient mice. Exp Med 654:391–419.

Lee YH, Kim JH, Song GG (2013) Pathway analysis of a genome-wide association study in schizophrenia and bipolar disorder. JAMA Psychiatry 71:1323–1331.

Kushima I, Nakamura Y, Abe KS, Ikeda M, Yotaki R, Okochi T, Fukuo Y, Ujiike H, Suzuki M, Inada T, Hashimoto R, Takeda M, Kaimori Y, Iwata N, Ozaki N (2012) Resequencing and association analysis of the KALRN and EPHB1 genes and their contribution to schizophrenia susceptibility. Schizophr Bull 38:552–560.

Lawrence D, Hancock KJ, Kisely S (2013) The gap in life expectancy from preventable physical illness in psychiatric patients in Western Australia: retrospective analysis of population based registers. BMJ 346:f2539.

Lee YH, Kim JH, Song GG (2013) Pathway analysis of a genome-wide association study in schizophrenia. Gene 525:107–115.

Li J, Zhou G, Ji W, Feng G, Zhao Q, Liu J, Li T, Li Y, Chen P, Zeng Z, Wang T, Hu Z, Zheng L, Wang Y, Shen Y, He L, Shi Y (2011) Common variants in the BCL9 gene conferring risk of schizophrenia. Arch Gen Psychiatry 68:232–240.

Lim JE, Hong KW, Jin HS, Kim YS, Park HK, Oh B (2010) Type 2 diabetes genetic association database manually curated for the study design and odds ratio. BMC Med Inform Decis Mak 10:76.

Lin PI, Shuldiner AR (2010) Rethinking the genetic basis for comorbidity of schizophrenia and type 2 diabetes. Schizophrenia Res 123:234–243.

Lis M, Stańczykiewicz B, Liskiewicz P, Misiak B (2020a) Impaired hormonal regulation of appetite in schizophrenia: a narrative review dissecting intrinsic mechanisms and the effects of antipsychotics. Psychoneuroendocrinology 119:104744.

Lis M, Stańczykiewicz B, Pawlik-Sobecka I, Samochowiec A, Reginia A, Misiak B (2020b) Assessment of appetite-regulating hormones provides further evidence of altered adipoin-sular axis in early psychosis. Front Psychiatry 11:480.

Liu Y, Li Z, Zhang M, Deng Y, Yi Z, Shi T (2013) Exploring the pathogenetic association between schizophrenia and type 2 diabetes mellitus diseases based on pathway analysis. BMC Med Genomics 6(Suppl 1):S17.

Liu Z, Habener JF (2010) Wnt signaling in pancreatic islets. Adv Exp Med Biol 654:391–419.

Lovestone S, Killick R, Di Forti M, Murray R (2007) Schizophrenia as a GSK-3 dysregulation disorder. Trends Neurosci 30:142–149.

Lu F, Qian Y, Li H, Dong M, Lin Y, Du J, Lin Y, Chen J, Shen C, Jin G, Dai J, Hu Z, Shen H (2012) Genetic variants on chromosome 6p21.1 and 6p22.3 are associated with type 2 diabetes risk: a case-control study in Han Chinese. J Hum Genet 57:320–325.

Luo X, Huang L, Han L, Luo Z, Hu F, Tieu R, Gan L (2014) Systematic prioritization and integrative analysis of copy number variations in schizophrenia reveal key schizophrenia susceptibility genes. Schizophr Bull 40:1285–1299.

Lyssenko V, Jonsson A, Almgren P, Pulzti N, Isomaa B, Tuomi T, Berglund G, Alshuler D, Nilsson P, Groop L (2008) Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med 359:2220–2232.

Ma JH, Sun XY, Guo TJ, Barot E, Wang DF, Yan LL, Ni DW, Huang NH, Xie Q, Zeng J, Ou-Yang L, Liu YQ, Lu Q (2018) Association on DISC1 SNPs with schizophrenia risk: a meta-analysis. Psychiatry Res 270:306–309.

Maas DA, Vallés A, Martens GJM (2017) Oxidative stress, prefrontal cortex hypomyelination and cognitive symptoms in schizophrenia. Transl Psychiatry 7:e1171.

MacDonald BT, Tamai K, He X (2009) Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 17:9–26.

Mao Y, Ge X, Frank CL, Madison JM, Koehler AN, Doud MK, Tassa C, Berry EM, Soda T, Singh KK, Biechele T, Petryshen TL, Moon RT, Haggarty SJ, Tsai LH (2009) Disrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3beta/beta-catenin signaling. Cell 136:1017–1031.

Marshall CR, et al.; Psychosis Endophenotypes International Consortium; CNV and Schizophrenia Working Groups of the Psychiatric Genomics Consortium (2017) Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. Nat Genet 49:27–35.

Martin PM, Stanley RE, Ross AP, Freitas AE, Moger CE, Brunbeck AC, lfraiti J, Stapornwongkul KS, Dominguez S, Kivimäe S, Mulligan KA, Pirooznia M, McCombie WR, Potash JB, Zandi PP, Purcell SM, Sanders SJ, Zuo Y, Sohal VS, Cheyette BNR (2018) DIXDC1 contributes to psychiatric susceptibility by regulating dendritic spine and glutamatergic synapse density via GSK3 and Wnt/β-catenin signaling. Mol Psychiatry 23:467–475.

McCluskey TH, Hoffman RE (2000) Schizophrenia as a disorder of developmentally reduced synaptic connectivity. Arch Gen Psychiatry 57:637–648.

Medzhidov R (2010) Inflammation 2010: new adventures of an old flame. Cell 140:771–776.

Meneses MJ, Silvestre R, Sousa-Lima I, Macedo MP (2019) Paraoxonase-1 as a regulator of glucose and lipid homeostasis: impact on the onset and progression of metabolic disorders. Int J Mol Sci 20:4049.

Menini T, Gugliucci A (2014) Paraoxonase 1 in neurological disorders. Redox Rep 19:49–58.

Meyer U (2013) Developmental neuroinflammation and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 42:20–34.

Millar JK, Christie S, Porteous DJ (2003) Yeast two-hybrid screens implicate DISC1 in brain development and function. Biochem Biophys Res Commun 311:1019–1025.

Miller BJ, Buckley PF, McEvoy JP (2018) Inflammation, substance use, psychopathology, and cognition in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Schizophr Res 195:275–282.

Misiak B (2019) Stress, allostatic load, and psychosis: one step forward in research but where to go next? Front Psychiatry 10:937.

Misiak B, Frydecka D, Zawadzki M, Kreflt M, Kiejna A (2014) Refined and integrating schizophrenia pathophysiology - relevance of the allostatic load concept. Neurosci Biobehav Rev 45:183–201.
Misiak B, Bartoli F, Stramecki F, Samochowiec J, Lis M, Kasznia J, Jarosz K, Stańczykiewicz B (2019) Appetite regulating hormones in first-episode psychosis: a systematic review and meta-analysis. Neurosci Biobehav Rev 102:362–370.

Misiak B, Wisniewski M, Lis M, Samochowiec J, Stanczykiewicz B (2020) Glucose homeostasis in unaffected first-degree relatives of schizophrenia patients: a systematic review and meta-analysis. Schizophr Res 232:2–8.

Mitchell AJ, Vancampfort D, De Herdt A, Yu W, De Hert M (2013) Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients. Schizophr Bull 39:295–305.

Mizuki Y, Takaki M, Okahisa Y, Sakamoto S, Kodama M, Uchijke H, Uchitomi Y (2014) Human Rho guanine nucleotide exchange factor 11 gene is associated with schizophrenia in a Japanese population. Hum Psychopharmacol 29:552–558.

Mizuki Y, Takaki M, Sakamoto S, Okamoto S, Kishimoto M, Okahisa Y, Itoh M, Yamada N (2016) Human rho guanine nucleotide exchange factor 11 (ARHGEF11) regulates dendritic morphogenesis. Int J Mol Sci 18:67.

Mtiraoui N, Ezzidi I, Chaieb M, Marmouche H, Aouni Z, Chaieb A, Mizuki Y, Takaki M, Okahisa Y, Itoh M, Yamada N (2016) Human rho guanine nucleotide exchange factor 11 (ARHGEF11) regulates dendritic morphogenesis. Int J Mol Sci 18:67.

Murphy KC, Jones LA, Owen MJ (1999) High rates of schizophrenia related risks for diabetes mellitus in young people with velo-cardio-facial syndrome. Arch Gen Psychiatry 56:940–945.

Murray CJ, et al. (2012) Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2197–2223.

Müller N (2018) Inflammation in schizophrenia: pathogenetic aspects and therapeutic considerations. Schizophr Bull 44:973–982.

Murphy KC, Jones LA, Owen MJ (1999) High rates of schizophrenia in adults with velo-cardio-facial syndrome. Arch Gen Psychiatry 56:940–945.

Murray CJ, et al. (2012) Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2197–2223.

Murphy KC, Jones LA, Owen MJ (1999) High rates of schizophrenia in adults with velo-cardio-facial syndrome. Arch Gen Psychiatry 56:940–945.

Murray CJ, et al. (2012) Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2197–2223.

Murphy KC, Jones LA, Owen MJ (1999) High rates of schizophrenia in adults with velo-cardio-facial syndrome. Arch Gen Psychiatry 56:940–945.

Murray CJ, et al. (2012) Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2197–2223.

Nagalski A, Kozinski K, Wisniewska MB (2016) Metabolic pathways in the periphery and brain: contribution to mental disorders? Int J Biochem Cell Biol 80:19–30.

Nakamura Y, Kaneto H, Miyatsuuka T, Matsuoka TA, Matsuhisa M, Node K, Hori M, Yamasaki Y (2006) Marked increase of insulin resistance and type 2 diabetes in Swedish men. Exp Clin Endocrinol Diabetes 114:282–287.

Nieuwen H, Galsgaard ED, Meldrup A, Friedrichsen BN, Billestrup N, Hansen JA, Lee YC, Carlsson C (2001) Regulation of beta-cell mass by hormones and growth factors. Diabetes 50(Suppl 1):S25–S29.

Nieto M, Cash-Padgett T, Kubo KI, Saito A, Ishii K, Sumitomo A, Taniguchi Y, Ishizuka K, Jaaro-Peled H, Tomoda T, Nakajima K, Sawa A, Kamiya K (2016) DISC1 a key molecular lead in schizophrenia. Mol Psychiatry 21:1488–1489.

Nordman S, Ding B, Ostenson CG, Kärvestedt L, Brismar K, Efendic S, Gu HF (2005) Leu7Pro polymorphism in the neuropeptide Y (NPY) gene is associated with impaired glucose tolerance and type 2 diabetes in Swedish men. Exp Clin Endocrinol Diabetes 113:282–287.

Nuevo R, Chatterji S, Fragaus D, Verdes E, Naidoo N, Arango C, Ayuso-Mateos JL (2011) Increased risk of diabetes mellitus among persons with psychotic symptoms: results from the WHO World Health Survey. J Clin Psychiatry 72:1592–1599.

Nyblom HK, Bugliani M, Fung E, Boggi U, Zubarev R, Marchetti P, Bergsten P (2009) Apoptotic, regenerative, and immune-related signaling in human islets from type 2 diabetes individuals. J Proteome Res 8:5650–5656.

Oh SJ, Fan X (2019) The possible role of the angiotensin system in the pathophysiology of schizophrenia: implications for pharmacotherapy. CNS Drugs 33:539–547.

Olsson M, Gerhard T, Huang C, Crystal S, Stroup TS (2015) Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry 72:1172–1181.

Olfson M, Gerhard T, Huang C, Crystal S, Stroup TS (2015) Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry 72:1172–1181.

Pau CE, Yu HS, Kim JJ, Kim W, Lee CU, Lee SJ, Jun TY, Lee C, Paik IH, Serretti A (2004) Glutathione S-transferase M1 polymorphism may contribute to schizophrenia in the Korean population. Psychiatr Genet 14:147–150.

Papadopoulou S, Edlund H (2005) Attenuated Wnt signaling perturbs pancreatic growth but not pancreatic function. Diabetes 54:2844–2851.

Pedersen CB, Mors O, Bertelsen A, Walloft B, Agerbo E, McGrath JJ, Mortensen PB, Eaton WS (2014) A comprehensive nationwide study of the incidence rate and lifetime risk for treated mental disorders. JAMA Psychiatry 71:573–581.

Perry BI, McIntosh G, Weich S, Singh S, Rees K (2016) The association between first-episode psychosis and abnormal glycemic control: systematic review and meta-analysis. Lancet Psychiatry 3:1049–1058.

Philippe A, Vaiva G, Casadebaig F (2005) Data on diabetes from the French cohort study in schizophrenia. Eur Psychiatry 20(Suppl 4):S340–S344.

Pickup JC (2004) Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 27:813–823.

Pillinger T, Beck K, Gobija C, Donocik JC, Jauhar S, Howes OD (2017) Impaired glucose homeostasis in first-episode schizophrenia: a systematic review and meta-analysis. JAMA Psychiatry 74:261–269.

Piotrowski P, Kowalczyk K, Rymaszewska J, Beszlej JA, Plichta P, Samochowiec J, Kalinowska S, Trzesniowska-Drukala B, Misiak B (2019) Allostatic load index and its clinical correlates at various stages of psychosis. Schizophr Res 210:73–80.

Popovic DC, Schmitt A, Kaurani L, Senner F, Papilow S, Malchow B, Fischer A, Schulze TG, Koutsouleris N, Falkai P (2019) Childhood trauma in schizophrenia: current findings and research perspectives. Front Neurosci 13:274.

Postolache TT, Del Bosque-Plata L, Jabbour S, Vergare M, Wu R, Gragnoli C (2019) Co-shared genetics and possible risk gene pathway partially explain the comorbidity of schizophrenia, major depressive disorder, type 2 diabetes, and metabolic syndrome. Am J Med Genet B Neuropsychiatr Genet 180:186–203.

Prabhanjan M, Suresh RV, Murthy MN, Ramachandra NB (2016) Type 2 diabetes mellitus disease risk genes identified by genome wide copy number variation scan in normal populations. Diabetes Res Clin Pract 113:160–170.

Rajkumar AP, Horsdal HT, Wimberley T, Cohen D, Mors O, Børglum AD, Gasse C (2017) Endogenous and antipsychotic-related risks for diabetes mellitus in young people with schizophrenia: a Danish population-based cohort study. Am J Psychiatry 174:686–694.

Rajkumar RP (2014) Prolactin and psychopathology in schizophrenia: No-More Disrupted-in-morphogenesis. Int J Biochem Cell Biol 80:19–30.

Ramsey JM, Schwarz E, Guest PC, van Beveren NJ, Leweke FM, Rothermundt M, Bogerts B, Steiner J, Bahn S (2013) Distinct molecular phenotypes in male and female schizophrenia patients. PLoS One 8:e78729.
Rasmussen AH, Rasmussen HB, Silahtaroglu A (2017) The DLGAP family: neuronal expression, function and role in brain disorders. Mol Brain 10:43.

Rehman K, Akash MS (2016) Mechanisms of inflammatory responses and development of insulin resistance: how are they interlinked? J Biomed Sci 23:87.

Reinehr T (2019) Inflammatory markers in children and adolescents with type 2 diabetes mellitus. Clin Chim Acta 496:100–107.

Rodríguez B, Nani JV, Almeida PGC, Brietzke E, Lee RS, Hayashi MA (2020) Neuropeptides and oligopeptides in schizophrenia. Neurosci Biobehav Rev 108:679–693.

Rümenapp U, Blomquist A, Schwörrer G, Schablowius H, Psoma A, Jakobs KH (1999) Rho-specific binding and guanine nucleotide exchange catalysis by KIAA0380, a dbl family member. FEMS Lett 459:313–318.

Ryan MC, Sharifi N, Condren R, Thakore JH (2004) Evidence of diabetogenic effects of statins in children and their family members. Clin Rheumatol 23:571–577.

Sudarov A, Gooden F, Tseng D, Gan WB, Ross ME (2013) Lis1 controls dynamics of neuronal filopodia and spines to impact synaptogenesis and social behaviour. EMBO Mol Med 5:591–607.

Takaki M, Kodama M, Mizuki Y, Kawai H, Yoshimura B, Kishimoto M, Sakamoto S, Okahisa Y, Yamada N (2018) Effects of the antipsychotics haloperidol, clozapine, and aripiprazole on the dendritic spine. Eur Neuropsychopharmacol 28:610–619.

Tang ST, Wang CJ, Tang HQ, Zhang Q, Wang Y (2013) Evaluation of glutathione S-transferase genetic variants affecting type 2 diabetes susceptibility: a meta-analysis. Gene 530:301–308.

Tomásik J, Lago SG, Vázquez-Bourgion J, Papiol S, Suárez-Finilla P, Crespo-Facorro B, Bahn S (2019) Association of insulin resistance with schizophrenia polygenic risk score and response to antipsychotic treatment. JAMA Psychiatry 76:864–867.

Tropea D, Hardingham N, Millar K, Fox K (2018) Mechanisms underlying the role of DISC1 in synaptic plasticity. J Physiol 596:2747–2771.

Tunbridge EM, Harrison PJ, Weinberger DR (2006) Catechol-o-methyltransferase, cognition, and psychosis: Val158Met and beyond. Biol Psychiatry 60:141–151.

Tziouvidi M, Stefanidis I, Stavridos K, Zintzaras E (2019) Identification of chromosomal regions linked to diabetic nephropathy: a meta-analysis of genome-wide linkage scans. Genet Test Mol Biomarkers 23:105–117.

Upthegrove R, Manzanares-Teson N, Barnes NM (2014) Cytokine function in medication-naïve first episode psychosis: a systematic review and meta-analysis. Schizophr Res 155:101–108.

Van Aelst L, D’Souza-Schorey C (1997) Rho GTPases and signaling networks. Genes Dev 11:2295–2322.

van Beveren NJ, Schwarz E, Noll R, Guest PC, Meijer C, de Haan L, Bahn S (2014) Evidence for disturbed insulin and growth hormone signaling as potential risk factors in the development of schizophrenia. Transl Psychiatry 4:e430.

van den Brink WJ, Palec S, Köhler I, de Lange ECM (2018) Access to the CNS: biomarker strategies for dopaminergic treatments. Pharm Res 35:64.

Voll SL, Boot E, Butcher NJ, Cooper S, Heung T, Chow EW, Silverstones CK, Bassett AS (2017) Obesity in adults with 22q11.2 deletion syndrome. Genet Med 19:204–208.

Wagner R, Heni M, Linder K, Ketterer C, Peter A, Röhm A, Hatzigelaki E, Stefan N, Staiger H, Häring HU, Fritsche A (2014) Age-dependent association of serum prolactin with glycaemia and insulin sensitivity in humans. Acta Diabetol 51:71–78.

Walker E, Mittal V, Tessner K (2008) Stress and the hypothalamic pituitary adrenal axis in the developmental course of schizophrenia. Annu Rev Clin Psychol 4:189–216.

Walker EF, Trotman HD, Pearce BD, Addington J, Cadenhead KS, Cornblatt BA, Heinsen R, Mathalon DH, Perkins DO, Seidman LJ, Tsuang MT, Cannon TD, McGlashan TH, Woods SW (2013) Cortisol levels and risk for psychosis: initial findings from the North American prodrome longitudinal study. Biol Psychiatry 74:410–417.

Wan J, Li Y, Zhang Z, Sun Z, He Y, Li R (2018) Methylenetetrahydrofolate reductase and psychiatric diseases. Transl Psychiatry 8:242.

Wang J, Zhang J, Li L, Wang Y, Wang Q, Zhai Y, You H, Hu D (2013) Association of rs12255372 in the TCF7L2 gene with type 2 diabetes susceptibility: a meta-analysis. Genet Test Mol Biomarkers 17:604–611.
activity-dependent structural and functional plasticity of dendritic spines. Neuron 56:640–656.
Xiu L, Lin M, Liu W, Kong D, Liu Z, Zhang Y, Ouyang P, Liang Y, Zhong S, Chen C, Jin X, Fan X, Qin J, Zhao X, Rao S, Ding Y (2015) Association of DRD3, COMT, and SLC6A4 gene polymorphisms with type 2 diabetes in southern Chinese: a hospital-based case-control study. Diabetes Technol Ther 17:580–586.
Xu Y, Ren J, Ye H (2018) Association between variations in the disrupted in schizophrenia 1 gene and schizophrenia: a meta-analysis. Gene 651:94–99.
Yoshikawa T, Naito Y (2002) What is oxidative stress? JMAJ 45:271–276.
Zhang J, Liu H, Yan H, Huang G, Wang B (2013a) Null genotypes of GSTM1 and GSTT1 contribute to increased risk of diabetes mellitus: a meta-analysis. Gene 518:405–411.
Zhang X, Hui L, Liu Y, Wang ZQ, You Y, Miao LN, Sun SL, Guan SL, Xiang Y, Kosten TR, Zhang XY (2013b) The type 2 diabetes mellitus susceptibility gene IGF2BP2 is associated with schizophrenia in a Han Chinese population. J Clin Psychiatry 74:e287–e292.
Zhou Y, Park SY, Su J, Bailey K, Ottosson-Laakso E, Shcherbina L, Oskolkov N, Zhang E, Thevenin T, Fadista J, Benett H, Vikman P, Wierup N, Fex M, Runge J, Wollheim C, Nobrega M, Renström E, Groop L, Hansson O (2014) TCF7L2 is a master regulator of insulin production and processing. Hum Mol Genet 23:6419–6431.